BioXcel Therapeutics
Stock Forecast, Prediction & Price Target
BioXcel Therapeutics Financial Estimates
BioXcel Therapeutics Revenue Estimates
BioXcel Therapeutics EBITDA Estimates
BioXcel Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $375K 0% | $1.38M 268% | Avg: $10.41M Low: $9.15M High: $11.33M avg. 655.05% | Avg: $27.01M Low: $23.72M High: $29.37M avg. 159.24% | Avg: $63.7M Low: $55.94M High: $69.27M avg. 135.81% | Avg: $106.2M Low: $93.27M High: $115.48M avg. 66.71% |
Net Income
% change YoY
| $-106.63M N/A | $-171.84M -61.16% | $-179.05M -4.19% | Avg: $-89.75M Low: $-110.43M High: $-30.87M avg. 49.87% | Avg: $-71.2M Low: $-49.35M High: $-18.93M avg. 20.67% | Avg: $-20.68M Low: $-23.03M High: $-17.40M avg. 70.95% | Avg: $-9.46M Low: $-10.54M High: $-7.96M avg. 54.22% |
EBITDA
% change YoY
| $-106.93M N/A | $-157.54M -47.32% | $-165.42M -4.99% | Avg: $2.08M Low: $1.83M High: $2.26M avg. 101.25% | Avg: $5.40M Low: $4.74M High: $5.87M avg. 159.24% | Avg: $12.73M Low: $11.18M High: $13.85M avg. 135.81% | Avg: $21.23M Low: $18.65M High: $23.09M avg. 66.71% |
EPS
% change YoY
| -$4.04 N/A | -$6.13 -51.73% | -$6.15 -0.32% | Avg: -$1.88 Low: -$3.79 High: -$1.06 avg. 69.39% | Avg: -$1.07 Low: -$1.69 High: -$0.65 avg. 43.07% | Avg: -$0.71 Low: -$0.79 High: -$0.6 avg. 33.73% | Avg: -$0.33 Low: -$0.36 High: -$0.27 avg. 54.22% |
Operating Expenses
% change YoY
| $106.93M N/A | $160M 49.62% | $171.90M 7.43% | Avg: $514.01M Low: $451.43M High: $558.97M avg. 199.01% | Avg: $1.33B Low: $1.17B High: $1.44B avg. 159.24% | Avg: $3.14B Low: $2.75B High: $3.41B avg. 135.81% | Avg: $5.23B Low: $4.60B High: $5.69B avg. 66.71% |
FAQ
What is BioXcel Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 48.93% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -110.43M, average is -89.75M and high is -30.87M.
What is BioXcel Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 254.20% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $9.15M, average is $10.41M and high is $11.33M.
What is BioXcel Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 50.10% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$3.79, average is -$1.88 and high is $-1.06.
What is the best performing analyst?
In the last twelve months analysts have been covering BioXcel Therapeutics stock. The most successful analyst is Raghuram Selvaraju.